Huntington Medical Research Institutes
Huntington Medical Research Institutes
News Article | April 17, 2017
— The “Cochlear Implants Market - Medical Devices Pipeline Assessment, 2017” report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cochlear Implants pipeline products. Browse the 66 Tables and Figures, 16 Companies, Spread across 54 Pages Report Available at http://www.reportsnreports.com/contacts/discount.aspx?name=958617. Scope of the Report: Extensive coverage of the Cochlear Implants under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of Cochlear Implants and list all their pipeline projects The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage The report provides key clinical trial data of ongoing trials specific to pipeline products Recent developments in the segment / industry Companies are mentioned: Advanced Bionics, Ceragenix Pharmaceuticals, Inc. (Inactive), Hannover Medical School, Huntington Medical Research Institutes, Labyrinth Devices, Northwestern University, Oticon Medical AB, OtoKinetics (Inactive), Sonova Holding AG, Tel Aviv Sourasky Medical Center, The University of Utah, Trinity College Dublin, University of Michigan, University of Michigan Pediatric Device Consortium and University of Wisconsin Madison. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=958617. Cochlear Implants Market- Recent Developments : Feb 20, 2017: Announcing Health Canada approval of the New HiRes Ultra Cochlear Implant 34 Nov 14, 2016: First Half Results 2016/17: Sonova with Strong Foundation for Further Growth 34 Oct 11, 2016: Sonova announces appointment of Group Vice President Retail 38 Sep 29, 2016: Cochlear launches the world's thinnest, full length perimodiolar electrode for cochlear implants 38 Sep 29, 2016: Cochlear: Retirement Of Chief Financial Officer 39 Sep 20, 2016: UNC hearing loss experts lead clinical trials of FDA-approved hearing implant 39 Sep 20, 2016: NEO Tech Offers Microelectronics Miniaturization for Medical Implantable Device OEMs 40 List of Tables Table 1: Cochlear Implants - Pipeline Products by Stage of Development Table 2: Cochlear Implants - Pipeline Products by Segment Table 3: Cochlear Implants - Pipeline Products by Territory Table 4: Cochlear Implants - Pipeline Products by Regulatory Path Table 5: Cochlear Implants - Pipeline Products by Estimated Approval Date Table 6: Cochlear Implants - Ongoing Clinical Trials Table 7: Cochlear Implants Companies - Pipeline Products by Stage of Development Table 8: Cochlear Implants - Pipeline Products by Stage of Development Table 9: Advanced Bionics LLC Pipeline Products & Ongoing Clinical Trials Overview Table 10: Hires Fidelity 120 Pediatrics - Product Status List of Figures Figure 1: Cochlear Implants - Pipeline Products by Stage of Development Figure 2: Cochlear Implants - Pipeline Products by Segment Figure 3: Cochlear Implants - Pipeline Products by Territory Figure 4: Cochlear Implants - Pipeline Products by Regulatory Path Figure 5: Cochlear Implants - Pipeline Products by Estimated Approval Date Figure 6: Cochlear Implants - Ongoing Clinical Trials Complete Table of Content is Available at http://www.reportsnreports.com/reports/958617-cochlear-implants-medical-devices-pipeline-assessment-2017.html. About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/958617-cochlear-implants-medical-devices-pipeline-assessment-2017.html
News Article | November 9, 2016
PASADENA, CA, November 09, 2016 /24-7PressRelease/ -- Huntington Medical Research Institutes (HMRI), an independent, leading biomedical research institute based in Pasadena, California, has announced the appointment of Allyson Simpson as Vice President of Philanthropy and Susie Silk Berry as Director of Philanthropy. Prior to joining HMRI, Allyson Simpson was the Senior Director of Gift Planning at California Institute of Technology (Caltech) in Pasadena for six years. Simpson also served as associate director of gift planning at Cedars-Sinai Medical Center in Los Angeles. Before she transitioned into development with a focus on planned, major and leadership giving, Simpson practiced corporate and regulatory law in Los Angeles for 25 years. She is a member of the Partnership for Philanthropic Planning - Los Angeles, where she has been appointed as President-Elect in 2016-2017 and will serve as President in 2017-2018. Simpson is currently Chair of the South Central Los Angeles Ministry Project Development Committee and is a member of the Mayfield Junior School Development Committee. Susie Berry will bring more than a decade of development experience to HMRI as the new Director of Philanthropy. Her new duties will include raising funds to further support the organization's biomedical research and development of new diagnostics and therapies. Prior to joining HMRI, Berry was the Director of Development at the YMCA in Los Angeles where she established goals, objectives and strategies to achieve annual revenue targets through major gifts, annual giving and foundation grants. Berry wrote grant proposals and managed the operations of the Chairman's Round Table annual funding driving sponsorships among other responsibilities. During her time with the YMCA, she successfully created the South Pasadena San Marino 5K/10K YRUN fundraiser through securing sponsors and exceeding the revenue goal by 20% through raising awareness of the Y's work in the community. "With their specialized skill sets and experience, both Simpson and Berry's work will make a tremendous impact in supporting our audacious scientific goals. They maintain strong ties in the philanthropic community and industry trade associations, and are well-respected in our community. They are true professionals who fit so well into the vision of HMRI," says Dr. Marie Csete, HMRI's President & Chief Scientist. "Simpson and Berry are exceptional, passionate individuals who will certainly make HMRI better known and better supported in our mission of changing lives through multidisciplinary, patient-focused research. I could not be happier with these new leaders of HMRI at this critical time in the organization's history with reinvigorated research programs and new labs under construction." About Huntington Medical Research Institutes Huntington Medical Research Institutes (HMRI) is a tax-exempt 501(c)(3) nonprofit, public-benefit organization based in Pasadena, California, dedicated to studying and enhancing knowledge of diseases in order to improve health and save lives. HMRI's mission is to change lives through multidisciplinary, patient-focused research. For six decades, it has been making biomedical discoveries and developments that have set new precedents in medical knowledge across the nation and around the world. HMRI is Pasadena's only independent, dedicated biomedical research organization with more than 47,000 square feet of research facilities focused on neurosciences (Alzheimer's, traumatic brain injury, migraine), cardiovascular, cell and tissue biology, advanced imaging, and liver, GI and GU research. For more information, visit: http://www.hmri.org
Ross B.D.,Huntington Medical Research Institutes
Expert Opinion on Drug Discovery | Year: 2013
Introduction: Magnetic resonance spectroscopy (MRS) will continue to play an ever increasing role in drug discovery because MRS does readily define biomarkers for several hundreds of clinically distinct diseases. Published evidence based medicine (EBM) surveys, which generally conclude the opposite, are seriously flawed and do a disservice to the field of drug discovery. Areas covered: This article presents MRS and how it has guided several hundreds of practical human 'drug discovery' endeavors since its development. Specifically, the author looks at the process of 'reverse-translation' and its influence in the expansion of the number of preclinical drug discoveries from in vivo MRS. The author also provides a structured approach of eight criteria, including EBM acceptance, which could potentially re-open the field of MRS for productive exploration of existing and repurposed drugs and cost-effective drug-discovery. Expert opinion: MRS-guided drug discovery is poised for future expansion. The cost of clinical trials has escalated and the use of biomarkers has become increasingly useful in improving patient selection for drug trials. Clinical MRS has uncovered a treasure-trove of novel biomarkers and clinical MRS itself has become better standardized and more widely available on 'routine' clinical MRI scanners. When combined with available new MRI sequences, MRS can provide a 'one stop shop' with multiple potential outcome measures for the disease and the drug in question. © 2013 Informa UK, Ltd.
Manoonkitiwongsa P.S.,Huntington Medical Research Institutes
CNS and Neurological Disorders - Drug Targets | Year: 2011
Therapeutic angiogenesis is a novel treatment for ischemic stroke, and vascular endothelial growth factor (VEGF) is a key angiogenic and neuroprotective pharmacological candidate for therapy. However, the greatest challenge of preclinical studies is demonstrating that VEGF-based therapeutic angiogenesis is safe and effective for ischemic stroke patients. This review presents the following crucial questions which must first be answered by preclinical studies before VEGF-based therapeutic angiogenesis advances to human stroke trials, (1) Does angiogenesis induced by VEGF monotherapy promote neuroprotection or further damage the nervous tissue? (2) Does angiogenesis by VEGF in combination with other agents (combination therapy) promote greater neuroprotection than monotherapy, and without additional side effects? (3) Which exogenous VEGF isoform best promotes angiogenesis and neuroprotection, with least adverse effects on other organs? (4) Does angiogenesis induced by exogenous VEGF produce similar results in different animal models of ischemic stroke, including variations in age, gender and coexisting chronic diseases? (5) Can angiogenesis be induced by exogenous VEGF without clinically-significant alterations of systemic hemodynamics? (6) Are gene therapy and stem cells more beneficial than recombinant protein for VEGF-based therapeutic angiogenesis? (7) What are the best routes, timing and duration for administering VEGF, and how do these parameters influence inflammation? (8) Does exogenous VEGF exacerbate inflammation when traumatic or other injuries are present with ischemia? (9) Are VEGF doses not causing tissue alterations at the light microscopy level associated with clinically-significant ultrastructural damages of the neurovascular unit? Both published and unpublished preclinical data from the author's laboratory are presented. © 2011 Bentham Science Publishers.
Tong M.J.,Huntington Medical Research Institutes |
Tong M.J.,University of California at Los Angeles |
Trieu J.,Huntington Medical Research Institutes
Journal of Digestive Diseases | Year: 2013
Objective: Hepatitis B virus (HBV) inactive carriers are HBV e antigen (HBeAg)-negative patients with normal alanine aminotransferase (ALT) levels and HBV DNA of ≤ 10000 copies/mL. We aimed to determine the clinical impact of ALT and HBV DNA elevations during the course of HBV infection. Methods: From January 1989 to January 2012, 146 inactive carriers were prospectively followed every 6-12 months with ALT and HBV DNA measurements and with hepatocellular carcinoma (HCC) surveillance. Results: During the follow-up of 8±6.3 years, 56 of the 146 patients maintained ALT ≤ 40U/L and HBV DNA≤10000copies/mL. However, 39 had rises of ALT > 40-80U/L and 4 had ALT > 80U/L; all except one reverted to baseline values. Also, during follow up, 69 (47.3%) inactive carriers had increases in HBV DNA of > 10000-999999 copies/mL; 38 of these patients' HBV DNA returned to baseline levels, while the remaining 31 patients maintained elevated HBV DNA values but had corresponding ALT of ≤ 40U/L. There were four liver-related outcomes: 129 (88.4%) remained "inactive carriers", 13 (8.9%) had loss of hepatitis B surface antigen (HBsAg), one (0.7%) had a spontaneous reactivation to HBeAg-negative chronic hepatitis, and two (1.4%) developed HCC. Conclusions: Although the prognosis of inactive carrier is favorable, transient ALT and HBV DNA elevations may be observed but have minimal clinical significance. Moreover, continuous HCC surveillance remains necessary since the risk of development still exists. © 2013 The Authors. Journal of Digestive Diseases © 2013 Wiley Publishing Asia Pty Ltd and Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine.
News Article | November 7, 2016
Huntington Medical Research Institutes (HMRI), an independent, leading biomedical research institute based in Pasadena, California, has announced the appointment of Allyson Simpson as Vice President of Philanthropy and Susie Silk Berry as Director..
Csete M.,Huntington Medical Research Institutes |
Doyle J.,California Institute of Technology
Interface Focus | Year: 2014
Blood glucose levels are controlled by well-known physiological feedback loops: high glucose levels promote insulin release from the pancreas, which in turn stimulates cellular glucose uptake. Low blood glucose levels promote pancreatic glucagon release, stimulating glycogen breakdown to glucose in the liver. In healthy people, this control system is remarkably good at maintaining blood glucose in a tight range despite many perturbations to the system imposed by diet and fasting, exercise, medications and other stressors. Type 1 diabetes mellitus (T1DM) results from loss of the insulin-producing cells of the pancreas, the beta cells. These cells serve as both sensor (of glucose levels) and actuator (insulin/glucagon release) in a control physiological feedback loop. Although the idea of rebuilding this feedback loop seems intuitively easy, considerable control mathematics involving multiple types of control schema were necessary to develop an artificial pancreas that still does not function as well as evolved control mechanisms. Here, we highlight some tools from control engineering used to mimic normal glucose control in an artificial pancreas, and the constraints, trade-offs and clinical consequences inherent in various types of control schemes. T1DM can be viewed as a loss of normal physiologic controls, as can many other disease states. For this reason, we introduce basic concepts of control engineering applicable to understanding pathophysiology of disease and development of physiologically based control strategies for treatment. © 2014 The Authors.
McCreery D.,Huntington Medical Research Institutes |
Pikov V.,Huntington Medical Research Institutes |
Troyk P.R.,Illinois Institute of Technology
Journal of Neural Engineering | Year: 2010
Activated iridium microelectrodes were implanted for 450-1282 days in the sensorimotor cortex of seven adult domestic cats and then pulsed for 240 h (8 h per day for 30 days) at 50 Hz. Continuous stimulation at 2 nC/phase and with a geometric charge density of 100 μC cm -2 produced no detectable change in neuronal density in the tissue surrounding the microelectrode tips. However, pulsing with a continuous 100% duty cycle at 4 nC/phase and with a geometric charge density of 200 μC cm -2 induced loss of cortical neurons over a radius of at least 150 μm from the electrode tips. The same stimulus regimen but with a duty cycle of 50% (1 s of stimulation, and then 1 s without stimulation repeated for 8 h) produced neuronal loss within a smaller radius, approximately 60 μm from the center of the electrode tips. However, there also was significant loss of neurons surrounding the unpulsed electrodes, presumably as a result of mechanical injury due to their insertion into and long-term residence in the tissue, and this was responsible for most of the neuronal loss within 150 μm of the electrodes pulsed with the 50% duty cycle. © 2010 IOP Publishing Ltd.
Fonteh A.N.,Huntington Medical Research Institutes
The journal of headache and pain | Year: 2013
Migraineurs are more often afflicted by comorbid conditions than those without primary headache disorders, though the linking pathophysiological mechanism(s) is not known. We previously reported that phosphatidylcholine-specific phospholipase C (PC-PLC) activity in cerebrospinal fluid (CSF) increased during migraine compared to the same individual's well state. Here, we examined whether PC-PLC activity from a larger group of well-state migraineurs is related to the number of their migraine comorbidities. In a case-control study, migraineurs were diagnosed using International Headache Society criteria, and controls had no primary headache disorder or family history of migraine. Medication use, migraine frequency, and physician-diagnosed comorbidities were recorded for all participants. Lumbar CSF was collected between the hours of 1 and 5 pm, examined immediately for cells and total protein, and stored at -80°C. PC-PLC activity in thawed CSF was measured using a fluorometric enzyme assay. Multivariable logistic regression was used to evaluate age, gender, medication use, migraine frequency, personality scores, and comorbidities as potential predictors of PC-PLC activity in CSF. A total of 18 migraineurs-without-aura and 17 controls participated. In a multivariable analysis, only the number of comorbidities was related to PC-PLC activity in CSF, and only in migraineurs [parameter estimate (standard error) = 1.77, p = 0.009]. PC-PLC activity in CSF increases with increasing number of comorbidities in migraine-without-aura. These data support involvement of a common lipid signaling pathway in migraine and in the comorbid conditions.
Charleswell C.A.,Huntington Medical Research Institutes
Ethnicity and Disease | Year: 2014
Despite efforts focused on outreach to minority populations, the literature reveals that the problem of disparities in minority involvement in clinical research persists. Thus, the objective of this article was to present an overview of the barriers to engage minorities in human subject research and the identification of promising strategies for their recruitment and retention. I identified a need for an innovative approach, which would focus recruitment efforts primarily on clinicians and researchers who contribute their own barriers to the process of recruitment and retention. In this way, the most common outreach efforts, which specifically focus on targeted minority groups, would be replaced. The inclusion of minorities in clinical research is an important bioethical issue, particularly when considering drug pharmacokinetics and pharmacodynamics, which may vary widely among different racial and ethnic populations. In conclusion, patient barriers to participation in clinical research are well-documented and remain of great importance; however, clinician and researcher barriers, equally as important, continue to be overlooked. Focusing on clinicians and researchers is needed to help increase their awareness about the barriers to minority participation that they may present. Continued research and efforts are needed to understand how best to identify, address, and overcome these barriers.